The FDA recently approved a biosimilar (CT-P13) to infliximab, which is used for treating people with IBD as well as people with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The new drug would be the first biosimilar monoclonal antibody approved in the United States.

Edward V. Loftus Jr., M.D., discusses some of the issues surrounding this medication and its potential benefits and drawbacks.